New York, USA – July 29, 2022 – Zebrafish platform, the mature division of Creative Biogene, is a biotech contract research organization specialized in zebrafish services. Zebrafish platform is supported by high technical expertise and top-class research facilities, combined with attractive strategic partnerships and academic collaborations, it is capable to offer multiple gene-editing services including but not limited to point mutations, knockout, short insertions, gene knock-in and conditional knock-in. Recently, Creative Biogene announced the release of its comprehensive zebrafish disease models to support drug discovery and toxicology research.
Creative Biogene has used a variety of methods to model human genetic diseases in zebrafish, providing zebrafish models that provide insights into human disease pathogenesis and associated drug discovery and toxicology, and allow the evaluation of novel small molecule inhibitors. Clones of mutated genes screened for specific phenotypes in zebrafish have similarities in humans and thus serve as models of human disease and study of underlying mechanisms. A variety of other mutants exhibiting similar phenotypes to human disease have been screened and identified. These include neurological disorders, cardiovascular disorders, blood disorders, muscle disorders and cancer, anxiety disorders, Parkinson’s disease and post-traumatic stress disorder.
Generation of stable zebrafish disease models developed by Creative Biogene includes genetic manipulation of zebrafish focused on random mutagenesis by chemical mutagens or retrovirus-mediated insertion methods. Meanwhile, robust methods involving the use of engineered nucleases, including ZFNs, TALENs, and CRISPR-Cas9 systems, have been used to generate stable human disease models, enabling the creation of specific zebrafish orthologs of interest. Targeted mutations. In addition, the CRISPR/Cas9 system is Creative Biogene’s powerful tool of choice for generating stable models of human genetic diseases in zebrafish.
Generation of transient zebrafish disease models supported by Creative Biogene can be achieved by morpholino-mediated knockdown of zebrafish orthologs of interest, allowing rapid examination of loss-of-function (LOF) phenotypes. CRISPR interference (CRISPRi) is another variant of the CRISPR/Cas9 system that can be used to reversibly silence the expression of target genes at the transcriptional level. It can be used to model LOF and gain phenotypes. It has the potential to be used on a large scale.
“Creative Biogene can utilize zebrafish models to help you explore reliable assay parameters for drug toxicity assessment. Our services can help you predict the safety of new compounds during the drug development process, and the results inform internal decision-making.” said Marcia Brady, the marketing director of Creative Biogene, she also added, “Creative Biogene can provide zebrafish high-throughput screening services to obtain focal images of zebrafish from head to tail with a large field of view and screen thousands of compounds in just a few days.”
About Creative Biogene
Creative Biogene, as a top-of-its-kind company that holds a leading position and is committed to accelerating the development of human science through biotechnology, offering innovative technologies, products, unique tools and services for research discoveries and product development. With more than 10 years of experience and in-house experts, Creative Biogene has become a well-recognized industry leader to support researchers worldwide.